International Journal of Life science and Pharma Reviews (IJLPR)  
   
  Aim and Scope - To publish peer reviewed review articles in rapidly developing field of Pharma and life sciences  
 
Article
Life Science
Volume 12 Issue 3, May 2022    Pages:14-20
The Increasing Prevalence of Diabetes Mellitus in COVID-19 Patients: Why?

Sufian Khalid, Khadeja Ismail Osman Farah, Awadalkareem AA., Musa Kheir, Hisham M. Abdelrahim, Motwakil lmam Awadelkareim, Ahmed Elsayed, Mohamed Osman Elamin, Ahmed A. Osman, Ali M. Alshehri, Hatim A
[View PDF]
DOI: http://dx.doi.org/10.22376/ijpbs/lpr.2022.12.3.L14-20
Abstract:
Coronavirus infection disease 2019 (COVID-19) is caused by SARS COV-2 and it has been increasing continuously in a number of cases and mortalities. COVID-19 had caused more than 197 million infections and 4 million deaths. This study aimed to assess the prevalence, risk factors and outcome of Diabetes Meletus (DM) among COVID-19 patients. Prospective, cross-sectional, hospital-based study conducted in which 400 COVID-19 patients enrolled in COVID-19 isolation centers in North Sudan. In this study, we noticed that most of the participants were males and constituted 275 (68.9%) of the study participants, the majority of participants’ ages ranged were between 40 to 60 years and was 150 (37.4%). The prevalence of DM was found to be 49.25% among the study participants. Diabetics were significantly more likely to have a respiratory rate higher than 30 (P=0.012), and oxygen saturation less than 93% (P<0.001), to develop shock (P=0.004), to require oxygen therapy (P<0.001), to be intubated (P<0.001), to develop respiratory failure and organ failure (P<0.001), and to have a poorer outcome (P<0.001). New-onset diabetes occurred in 20 (5%) participants and their mortality was higher compared to non-patients with diabetes (P=0.04). The total mortality of participants was 15.8%, factors associated with poorer outcomes were older age (P<0.001), and having type I diabetes (P=0.025).  The prevalence of diabetes is very high among COVID-19 patients, and is associated with a more severe disease and a poorer outcome. New onset diabetes was associated with poorer outcomes compared to non-diabetics. More researches requested to discover more risk factors and complications associated with Covid-19.
Keywords: COVID-19; DM; Diabetogenicity; Isolation Centers; Sudan
Full HTML:
  1. World Health Organization (WHO) Weekly Operational Update on COVID-19, 4 August 2021, Issue No. 66.
  2. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes MetabSyndrClin Res Rev [Internet]. 2020 May 1 [cited 2021 May 25];14(3):211–2. Available from: https://pubmed.ncbi.nlm.nih.gov/32172175/
  3. Akbar DH. Bacterial pneumonia: Comparison between diabetics and non-diabetics. ActaDiabetol [Internet]. 2001 [cited 2021 May 25];38(2):77–82. Available from: https://pubmed.ncbi.nlm.nih.gov/11757805/
  4. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med [Internet]. 2006 Jun [cited 2021 May 25];23(6):623–8. Available from: https://pubmed.ncbi.nlm.nih.gov/16759303/
  5. Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care [Internet]. 2010 Jul [cited 2021 May 25];33(7):1491–3. Available from: https://pubmed.ncbi.nlm.nih.gov/20587722/
  6. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis [Internet]. 2016 [cited 2021 May 25]; 49:129–33. Available from:https://pubmed.ncbi.nlm.nih.gov/27352628/
  7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet [Internet]. 2020 Feb 15 [cited 2021 May 25];395(10223):507–13. Available from: https://doi.org/10.1016/
  8. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet [Internet]. 2020 Mar 21 [cited 2021 May 25];395(10228): e52. Available from: https://pubmed.ncbi.nlm.nih.gov/32171074/
  9. EmanSheshah, Shaun Sabicob, et al, Prevalence of diabetes, management and outcomes among Covid-19 adult patients admitted in a specialized tertiary hospital in Riyadh, Saudi Arabia, Diabetes Research and Clinical Practice Volume 172, February 2021, 108538, https://doi.org/10.1016/j.diabres.2020.108538
  10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020 Feb 15 [cited 2021 May 26];395(10223):497–506. Available from: https://isaric.tghn.org/protocols/
  11. Livingston E?, Bucher K?.  Coronavirus disease 2019 (COVID-19) in Italy. ?JAMA. Published online March 17, 2020. doi:10.1001/jama.2020.4344
  12. Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res ClinPract [Internet]. 2020 Aug 1 [cited 2021 May 26]; 166:108347. Available from: /pmc/articles/PMC7375314/
  13. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, Khare S, Srivastava A. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes MetabSyndr. 2020 Jul-Aug;14(4):535-545. doi: 10.1016/j.dsx.2020.04.044. Epub 2020 May 6. PMID: 32408118; PMCID: PMC7200339.
  14. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May; 94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12. PMID: 32173574; PMCID: PMC7194638.
  15. Coronavirus disease 2019 (COVID-19): situation report-57. Published March 17, 2020. Accessed March 18, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200317-sitrep-57-covid-19.pdf?sfvrsn=a26922f2_2
  16. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA - J Am Med Assoc [Internet]. 2020 May 12 [cited 2021 May 26];323(18):1775–6. Available from: https://www.who.int/docs/default-
  17. Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes [Internet]. 2020 Dec 1 [cited 2021 May 26];12(12):895–908. Available from: /pmc/articles/PMC7405270/?report=abstract
  18. SKM Noor, SOE Busharaet al., Undiagnosed DM in rural communities in Sudan: prevalence and risk factors, Eastern Mediterranean Health Journal, 2015, Vol. 21, No. 3, page 164 - 170.
  19. Mohamed A.Eltom, AbubakrH.Babiker et AK., Increasing prevalence of type 2 DM and impact of ethnicity in north Sudan, Diabetes Research and Clinical Practice, Volume 136, February 2018, Pages 93-99.
  20. Elmadhoun WM, Noor SK, Ibrahim AA, Bushara SO, Ahmed MH. Prevalence of DM and its risk factors in urban communities of north Sudan: Population-based study. J Diabetes. 2016 Nov;8(6):839-846. doi: 10.1111/1753-0407.12364. Epub 2016 Feb 24. PMID: 26663723.
  21. Noor SK, Elmadhoun WM, Bushara SO, Ahmed MH. The Changing Pattern of Hospital Admission to Medical Wards: Burden of non-communicable diseases at a hospital in a developing country. Sultan QaboosUniv Med J. 2015 Nov;15(4): e517-22. doi: 10.18295/squmj.2015.15.04.013. Epub 2015 Nov 23. PMID: 26629380; PMCID: PMC4664098.
  22. Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res ClinPract. 2020 Sep; 167:108382. doi: 10.1016/j.diabres.2020.108382. Epub 2020 Aug 25. PMID: 32853686; PMCID: PMC7445123.
  23. John Hopkins Coronavirus Resource Center. COVID-19 Mortality Analyses [Internet]. 2021 May [cited 2021 May 27]. Available from: https://coronavirus.jhu.edu/data/mortality.
  24. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020 Mar 28 [cited 2021 May 27];395(10229):1033–4. Available from: https://pubmed.ncbi.nlm.nih.gov/32192578/
  25. Angelidi AM, Belanger MJ, Mantzoros CS. COVID-19 and DM: What we know, how our patients should be treated now, and what should happen next. Metabolism [Internet]. 2020 Jun 1 [cited 2021 May 27];107. Available from: https://pubmed.ncbi.nlm.nih.gov/32320742/
  26. Mathur A, Sadana D, Azad G. SARS Covid-19-Call of Threat: Attributes and Current Approach. International Journal of Pharma and Bio Sciences. 2021:41-5.

 

 
© 2010-2015 IJLPR rights reserved. Specialized onine journals by ubijournal. Website by Ubitech Solutions